Infinity Pharmaceuticals Stock Forecast, Price & News

Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

Is Infinity Pharmaceuticals a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals or view top-rated stocks.

How has Infinity Pharmaceuticals' stock price been impacted by Coronavirus?

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INFI shares have increased by 41.6% and is now trading at $1.43.
View which stocks have been most impacted by COVID-19.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 2,200,000 shares, a decrease of 19.7% from the December 15th total of 2,740,000 shares. Based on an average trading volume of 1,650,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 2.5% of the company's shares are short sold.
View Infinity Pharmaceuticals' Short Interest.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Infinity Pharmaceuticals.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) issued its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.12) EPS for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.02. The biotechnology company earned $0.43 million during the quarter, compared to analysts' expectations of $0.45 million. Infinity Pharmaceuticals had a negative trailing twelve-month return on equity of 172.12% and a negative net margin of 2,398.81%. During the same period last year, the company posted ($0.16) earnings per share.
View Infinity Pharmaceuticals' earnings history.

What price target have analysts set for INFI?

9 analysts have issued 1 year target prices for Infinity Pharmaceuticals' stock. Their forecasts range from $4.00 to $14.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $9.56 in the next twelve months. This suggests a possible upside of 568.2% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the following people:

• Adelene Q. Perkins, Chairman & Chief Executive Officer
• Lawrence E. Bloch, President & Treasurer
• Melissa Hackel, Vice President-Finance
• Robert Ilaria, Chief Medical Officer
• Stephane Peluso, Chief Scientific Officer

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Infinity Pharmaceuticals' key competitors?

Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Novavax (NVAX), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of INFI's competitors.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $1.43.

How much money does Infinity Pharmaceuticals make?

Infinity Pharmaceuticals has a market capitalization of $127.29 million and generates $1.72 million in revenue each year. The biotechnology company earns $-40.49 million in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Infinity Pharmaceuticals have?

Infinity Pharmaceuticals employs 23 workers across the globe.

When was Infinity Pharmaceuticals founded?

Infinity Pharmaceuticals was founded in 2000.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is www.infi.com.

Where are Infinity Pharmaceuticals' headquarters?

Infinity Pharmaceuticals is headquartered at 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at (617) 453-1000, via email at [email protected], or via fax at 617-453-1001.